NTLA
Intellia Therapeutics, Inc.
$15.44
-1.40 (-8.31%)
At close · Jul 9
Market Cap
$2.06B
Shares
139,722,277
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$67.67M
+16.9%
FY2025
Net Income
-$412.69M
+20.5%
FY2025
Gross Margin
100%
0pp
FY2021
Operating Margin
-651.67%
+271.4pp
FY2025
Diluted EPS
-$3.81
+27.4%
FY2025
Operating Cash Flow
-$394.74M
-13.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $66.09M | $67.67M | $57.88M | $36.28M | $52.12M | $33.05M | $57.99M | $43.1M | $30.43M | $26.12M | $16.48M | — | |
| — | — | — | — | — | $0 | $0 | $0 | $0 | — | — | — | |
| — | — | — | — | — | $33.05M | $57.99M | $43.1M | $30.43M | — | — | — | |
| — | — | — | — | — | 100% | 100% | 100% | 100% | — | — | — | |
| $361.17M | $388.86M | $466.31M | $435.07M | $419.98M | $229.81M | $150.41M | $108.41M | $89.12M | $67.65M | $31.84M | $11.17M | |
| $125.64M | $119.8M | $125.83M | $116.5M | $90.31M | $71.1M | $44.17M | $41.06M | $32.19M | $28.03M | $16.8M | $8.28M | |
| $9.47M | $9.77M | $10.29M | $8.98M | $7.57M | $6.89M | $6.31M | $5.59M | $4.46M | $2.99M | $1.1M | $328K | |
| $486.81M | $508.66M | $592.14M | $551.57M | $510.29M | $300.9M | $194.58M | $149.47M | $121.3M | $95.67M | $48.64M | $19.45M | |
| -$420.72M | -$440.99M | -$534.26M | -$515.29M | -$458.16M | -$267.85M | -$136.58M | -$106.37M | -$90.87M | -$69.56M | -$32.16M | -$13.41M | |
| — | -651.67% | -923.1% | -1420.51% | -879.04% | -810.37% | -235.51% | -246.78% | -298.58% | -266.32% | -195.15% | — | |
| -$411.24M | -$431.22M | -$523.98M | -$506.32M | -$450.59M | -$260.96M | -$130.27M | -$100.78M | -$86.41M | -$66.56M | -$31.06M | -$13.08M | |
| $25.8M | $29.2M | $47.81M | $49.83M | $8.54M | $1.28M | $2.35M | $6.84M | $5.53M | $2.01M | $525K | — | |
| $26.12M | $28.3M | $15.24M | $34.1M | -$16.02M | -$42K | $2.35M | $6.84M | — | — | — | — | |
| — | $0 | $0 | -$15.63M | -$11.08M | -$1.33M | $0 | $0 | — | — | — | — | |
| $1.22M | $0 | -$32.57M | $0 | $0 | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$67.54M | -$31.63M | -$13.41M | |
| — | $0 | — | — | — | — | — | — | — | — | $0 | -$1.01M | |
| -$394.6M | -$412.69M | -$519.02M | -$481.19M | -$474.19M | -$267.89M | -$134.23M | -$474.19M | -$85.34M | -$67.54M | -$31.63M | -$12.4M | |
| — | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | -1100.12% | -280.42% | -258.62% | -191.97% | — | |
| -$395.89M | -$412.27M | -$518.29M | -$475.99M | -$479.02M | -$270.53M | -$134.49M | -$99.24M | -$85.37M | -$67.54M | -$31.63M | — | |
| USD/shares | — | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 | -$2.40 | — | — | — | — | — |
| USD/shares | — | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 | -$2.40 | — | — | — | — | — |
| shares | — | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25K | 43.07M | 36.01M | 22.22M | 243K |
| shares | — | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25K | 43.07M | 36.01M | 22.22M | 243K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Biotechnology median 7.68×
Key facts
CIK
1652130
CUSIP
45826J105
13F (30d)
10 filings
10 filers
Visit website
Investor relations